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Abstract  8 
Cholesterol levels are strictly regulated to maintain its homeostasis therefore, if it is not 9 
absorbed with the diet, the cholesterol biosynthetic pathway is enhanced and vice versa. 10 
Nowadays, the commonly prescribed therapeutic treatments for hypocholesterolemic patients are 11 
targeted toward the reduction of both cholesterol intestinal absorption and/or its endogenous 12 
biosynthesis. But, when hypercholesterolemia is still moderate the consumption of food products 13 
with cholesterol-lowering capacities is more desirable than drugs. The marketed food 14 
supplemented with hypocholesterolemic compounds are only inhibiting mechanisms for 15 
cholesterol absorption (i.e. phytosterols, cereal β-glucans).  However, certain fungal extracts 16 
obtained from edible mushrooms might be able of modulating cholesterol levels by both strategies 17 
as pharmaceutical drugs and functional foods. In vitro and in vivo studies indicated that fungal 18 
sterols down-regulated genes involved in the cholesterol homeostasis (such as Srebf2 and Nr1h4 19 
(FXR)) and other specific mushroom extracts (β-glucans and other water-soluble compounds) also 20 
stimulated transcriptional profiles similar to simvastatin or ezetimibe (two hypocholesterolemic 21 
drugs). These and other observations suggested that the hypocholesterolemic effect of 22 
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mushrooms extracts could be due to transcriptional and post-transcriptional modulations besides 23 
other indirect effects.  24 
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1.  Introduction  39 
Although cardiovascular diseases (CVDs) incidence is decreasing over the last decades due to 40 
medical advances and advise, they are still the second leading cause of premature death in 41 
Western world after cancer1.  Already for many years, health authorities are reinforcing efforts to 42 
inform people about what CVD are, their main symptoms, their health consequences and the way 43 
to decrease the risk of suffering them.   44 
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CVD risks are influenced by genetic factors such as specific tendencies to obesity, hypertension, 45 
etc., gender or age however, many risk factors are also modulated by life style habits such as 46 
smoking, sedentary/sporting or in/adequate diets2 and this is the reason that CVDs are considered 47 
as multifactorial diseases.  48 
Several biomarkers are used to evaluate the real individual CVD risk i.e. elevated 49 
homocysteine, coronary artery calcium-phosphate calcification or elevated fibrinogen blood level 50 
but, the most useful marker for CVD risk is the LDL (low-density lipoprotein)-cholesterol 51 
concentration in serum, one of the major transport cholesterol complexes.  The LDL-cholesterol 52 
constitutes 60-70% of total serum cholesterol and a blood concentration higher than 200 mg/dL is 53 
considered, nowadays, as risky level3,4.   54 
Due to the increasing interest of modern society for natural products as agents able to 55 
decrease the consumption of pharmaceutical drugs, new food products with high levels of 56 
hypocholesterolemic compounds are being explored. Nowadays, the cholesterol-lowering effect 57 
of compounds such as plant sterols (phytosterols, phytostanols and derivatives)5,6; dietary fibers 58 
such as β-glucans or chitosans7; peptides such as those derivate from soy proteins8 or bovine milk 59 
β-lactoglobulins9 have been studied and therefore, several functional food products supplemented 60 
with these compounds are available at the supermarkets10-14. 61 
Some edible mushrooms species are able of lowering cholesterol levels in serum since they are 62 
a good source of fungal sterols (with high structural similarity to phytosterols), dietary fibers such 63 
as β-glucans and chitins (fungal polysaccharides), β-lactones, specific proteo/glucan complexes or 64 
compounds such as eritadenine10. Recent studies pointed out that ergosterol-enriched extracts 65 
and other fungal compounds were also able of modulating cholesterol-related gene expression in 66 
animal intestine and liver15.  67 
Therefore, in this work, the molecular events occurring during cholesterol synthesis and 68 
absorption are reviewed analyzing the influence of some hypocholesterolemic compounds 69 
obtained from edible mushrooms. 70 
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2. Cholesterol metabolism  71 
Cholesterol, together with phospholipids, modulates membrane fluidity influencing transport 72 
through them, permeability, configuration of membrane proteins or enzyme activities. 73 
Furthermore, cholesterol is involved in many metabolic pathways since it is a precursor of a wide 74 
range of biological molecules such as bile acids (i.e. cholic acid), steroids hormones (i.e. 75 
testosterone) and lipophilic vitamins (i.e. vitamin D3)7. This sterol is synthesized mainly in the liver, 76 
besides other organs such as adrenal glands, intestine or ovaries. But, it can also be incorporated 77 
from the diet after the digestion process. Thus, well-balanced mechanisms of cholesterol synthesis, 78 
bile acids catabolism, cholesterol intake and excretion through faeces will maintain healthy and 79 
stable cholesterol values in serum (homeostasis). Until few years ago, liver was considered the 80 
main control center of cholesterol homeostasis however, more recent studies pointed intestine as 81 
a tissue highly involved in the regulation of plasma cholesterol levels and homeostasis13,16,17. 82 
2.1. Molecular events occurring during cholesterol digestion  83 
Although food digestion in humans starts in mouth with the mechanical chewing and 84 
starch degradation by salivary enzymes (mastication), fat remains undigested until it reaches the 85 
stomach. Gastric digestion is mainly oriented toward protein degradation however, some lipid-86 
degraded enzymes are also active at this step. Afterwards, the main fat digestion take place in 87 
duodenal lumen where all lipid compounds from gastric bolus (including free or esterified diet 88 
cholesterol) are mixed with the bile and pancreatic juices. 89 
Cholesterol molecules from diet, bile, intestinal secretions and desquamated cells 90 
together with the bile secreted compounds such as phospholipids (lecithin) and bile acids (salts of 91 
taurocholic and deoxycholic acids, etc.) form small emulsified droplets. Then, pancreatic lipase, 92 
phospholipase A2 and cholesterol esterase transform the emulsified particles in a series of 93 
colloidal structures including vesicles, micelles or dietary mixed micelles (DMM)10. 94 
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2.2. Molecular events occurring during cholesterol absorption 95 
Most of the micellated lipid-like compounds are incorporated into the organism through 96 
the second part of small intestine (jejunum), except bile acids that can be absorbed at jejunum and 97 
ileum levels by an apical sodium-dependent bile acid transporter (ASBT)18,19. The SR-B1 scavenger 98 
receptor (encoded by SCARB1 gen in humans) mainly located at both apical and basolateral 99 
membranes17,20 of adrenal glands, hepatocytes and enterocytes (Figure 1), is involved in the 100 
regulation of the endocrine metabolism, vitamin absorption or bile secretion.  It also plays a role 101 
in the cholesterol transport through membranes as a receptor of HDL (high-density lipoprotein)-102 
cholesterol but not in the small intestine absorption context20,21. SR-B1 transport allows a passive 103 
bi-directional cholesterol efflux depending of concentration gradients22 pointing SR-B1 as an 104 
important modulator of reverse cholesterol transport (RCT) (described later)20. However, although 105 
SR-B1 contribute to enterocytic cholesterol absorption, recent studies demonstrated that 106 
Niemann-Pick C1-like protein (NPC1L1) is the main sterol transporter from the intestinal lumen to 107 
the enterocyte cytoplasm, being imperative for non-esterified cholesterol absorption23.  108 
NPC1L1 is involved in this transmembrane sterol efflux due to a sterol-sensing domain 109 
(SSD) and it is co-localized at the cellular and intracellular vesicular membranes. The distribution 110 
of non-esterified cholesterol determines the main location of NPC1L1 proteins. At low intracellular 111 
concentrations, NPC1L1 will be mostly exposed at the brush-border enterocyte membrane and it 112 
will be translocate inside the cell at high levels of non-esterified cholesterol24. In human, NPC1L1 113 
genes are not only expressed in enterocytes of small intestine but also in liver where they are 114 
expressed in large amounts. Human hepatocytic NPC1L1 protein is located at the canalicular 115 
membrane facilitating the uptake of newly secreted biliary cholesterol and therefore, showing a 116 
similar role that intestinal NPC1L120. Transcriptional regulation of NPC1L1 is not yet elucidated 117 
but, it seems to be influenced by sterol regulatory element-binding protein or SREBP2 (encoded 118 
by SREBF2 gene in humans) that are sensors activating different answers depending on the 119 
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intracellular cholesterol concentrations. At low cholesterol levels, SCAP (integral membrane 120 
protein) goes along with SREBP2 from endoplasmic reticulum (ER) to Golgi body (GB) for 121 
subsequent processing and activation. On contrary, at high or enough cholesterol levels SCAP-122 
SREBP2 complex is retained by INSIG proteins (Insulin induced gene 1 protein located in ER 123 
membrane) to avoid SREBP2 maturation impairing its transcription25. Moreover, other reports 124 
pointed PPARδ (peroxisome-proliferator-activated receptor δ) as another NPC1L1 modulator 125 
since down-regulation of the cholesterol transporter has been induced by PPARδ activation in 126 
mice11. 127 
Intracellular non-esterified cholesterol concentrations could also be modulated by ATP-128 
binding cassette (ABC) transporters such as ABCG5/ABCG8 and ABCA1, located respectively at 129 
apical and basolateral enterocyte sides. ABCG5 and ABCG8 proteins, expressed in liver and small 130 
intestine, are involved in the reverse cholesterol transport (RCT) of sterols, from intracellular 131 
environment to lumen. Independent expression of both genes is necessary for the proper function 132 
of this heterodimer26. Over-expression of ABCG5/8 heterodimer increases non-esterified 133 
cholesterol excretion to the lumen reducing its internal concentration and consequently inducing 134 
activation of cholesterol synthesis rate27. In small intestine, the ABCG5/8 gene expression seems 135 
to be regulated by a LXR-dependent member of nuclear receptor family named RXR (retinoid X 136 
receptor)26-28 while in liver, the heterodimer is directly modulated by LXR [30]. Apparently, the 137 
latter receptor, along with PPARδ, is also modulator of the ABCA1 expression10,26. ABCA1 is a 138 
transport protein directly involved in excretion of exceeding non-esterified cholesterol into HDL. 139 
LXR agonist administration or high cholesterol concentrations in the cytosol stimulate a direct 140 
effect on the transcriptional modulation of these transport proteins although its specific 141 
regulatory mechanisms remains still unclear. A protein-protein interaction with another 142 
transcription factor affecting the transcription rate of the ABC proteins have been hypothesized 143 
29. 144 
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Due to confusions noticed in several publications, it is worthy to define the specific role of 145 
two widely mentioned enzymes involved in the transferring of acyl groups within the cholesterol 146 
metabolism. Acetyl-Coenzime A transferase (ACAT) and Sterol O-acyltransferase (SOAT) are two 147 
enzymes belonging to the acyltransferases family however, they do not catalyze the same reaction 148 
(Table 1). ACAT isoforms (ACAT1/ACAT2) are responsible of the reversible formation of 149 
acetoacetyl-CoA from two molecules of acetyl-CoA. The ACAT1 and ACAT2 genes are respectively 150 
located in chromosome 11 (11q22.3) and chromosome 6 (6q25.3)30,31. However, SOAT isoforms 151 
(SOAT1/SOAT2) catalyze the formation of fatty acid-cholesterol esters from cholesterol and acyl-152 
CoA molecules and are encoded by two genes located respectively in loci 1q25.2 and 12q13.1332,33. 153 
Then, since some of the mentioned works along the text wrongly referred to ACAT when it should 154 
indicate SOAT, a personal advice (AvS mark) was made pointing attention where required. 155 
Once non-esterified cholesterol reaches the cytoplasm become a substrate of ACAT2(AvS), 156 
an integral membrane protein mainly expressed in small intestine and liver. ACAT2(AvS) decreases 157 
cytoplasmic amounts of non-esterified cholesterol promoting its esterification and integration 158 
into the ER pre-chylomicrons modulating the cholesterol transmembrane absorption rate from 159 
intestinal lumen34. It also plays an important role maintaining the dynamic equilibrium 160 
(homeostasis) between free-cholesterol and esterified-cholesterol35. More than 50% of sterols 161 
esterification within the enterocytes is carried out by ACAT2(AvS) with a higher affinity for 162 
cholesterol esterification rather than other non-cholesterol sterols.  163 
The internal ER triglycerides re-assemblage is carried out by several enzymes such as 164 
lysophosphatidate acyltransferase (AGPAT), phosphatidate phosphatase (LPAP), 2-acylglycerol O-165 
acyltransferase 2 (MGAT2) and diacylglycerol O-acyltransferase 1 (DGAT1). Then, esterified-166 
cholesterol together with the triglycerides is packed into pre-chylomicrons by the microsomal 167 
triglyceride transfer protein (MTTP) and the apolipoprotein B48 (an isoform derived from APOB 168 
gene characteristic of enterocytes). MTTP and APOB48 proteins constitute an active 169 
heterodimeric complex linked by ionic interactions with a particular feedback assembly and 170 
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secretion system i.e. the larger the APOB48 subunit is, the lower binding capacity with MTTP is 171 
noticed and less APOB48 is secreted. Therefore, the APOB48-MTTP binding process plays an 172 
important role in the lipoprotein biogenesis36-38.  173 
The combined regulatory effect of NPC1L1, ABCA1, ABCG5/8 and ACAT2(AvS) activities play 174 
a critical role in modulating the amount of esterified cholesterol that will be integrated in the pre-175 
chylomicrons with the assistance of the apolipoporotein B48 (APOB48), the microsomal 176 
triglyceride transfer protein (MTTP) and the diacylglicerol-o-acyltransferase (DGAT1/2)39.  177 
Once prechylomicrom structure is assembled, it is further transformed into chylomicron in the GB 178 
and excreted by exocytosis into the lymph system through enterocyte basolateral membrane. On 179 
the other hand, the non-esterified cholesterol remaining in the cytoplasm could bind to APOA1 180 
protein for a further transport to the lymphatic vessels leading to nascent HDL lipoproteins. Thus, 181 
HDL as well as chylomicrons are released free into the blood stream and transported to the liver 182 
and peripheral organs such as adrenal glands11. 183 
2.3. Molecular events occurring during cholesterol synthesis 184 
Total blood cholesterol levels are not only dependent on exogenous cholesterol absorption 185 
but also on endogenous cholesterol synthesis. Several tissues are involved in de novo cholesterol 186 
biosynthesis i.e. enterocytes, adrenal glands, ovaries or testicles but, mostly it is generated by 187 
hepatic cells. In fact, one of the liver´s main roles is the production of the bile salts from cholesterol 188 
as constitutive compounds of biliary fluids needed for the digestion processes while the cholesterol 189 
synthesized in adrenals glands or intestine is used respectively as hormone precursor and 190 
cholesterolemia modulator11. Cholesterol biosynthesis is carried out by a combination of 191 
mevanolate and steroid biosynthetic pathways 40(Figure 2).  192 
The 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is considered the key 193 
enzyme of cholesterol synthesis although the activities of many enzymes involved in the 194 
biosynthetic pathway such as ACAT2, hydroxymethylglutaryl-CoA synthase (HMGCS), Delta24-195 
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sterol reductase (DHCR24), farnesyl-diphosphate farnesyltransferase (FDFT1/SQS) or 7-196 
dehydrocholesterol reductase (DHCR7), are also susceptible of modulation. Recently, Gill et al. 197 
(2011) suggested that squalene monoxygenase (SQLE) might be the second critical modulatory 198 
point despite its lower specificity within the cholesterol metabolism compared to HMGCR (after in 199 
vitro experiments)41.   200 
However, other enzymes such as SQS and SQLE are also gaining attention as a potential 201 
stop-point of cholesterol biosynthesis because SQS it is involved in the transformation of farnesyl 202 
pyrophosphate into squalene, being the first specific reaction at the branching point between 203 
sterol and non-sterol biosynthesis. SQS transcriptional product and protein are modulated by 204 
cholesterol since low levels of this sterol activate the SQS promoter by sterol regulatory element 205 
binding proteins (mostly SREBP2). On the contrary, SQS mRNA concentration decreases as 206 
response of cholesterol excess. SQLE is a monoxygenase (also named squalene epoxidase) that 207 
catalyzes the next step after squalene transformation by SQS, a crucial oxygenation process 208 
yielding squalene 2,3-epoxide (Figure 2). Modulation of SQLE activity seems also cholesterol-209 
dependent and apparently regulation is mediated by proteosome activity41.  210 
The HMGCR includes seven domains inserted in ER (endoplasmic reticulum) membrane 211 
with an active carboxyl chain located at the cytosol. HMGCR is ubiquitously expressed i.e. immune 212 
(white blood cells), nervous, muscle, small intestine or reproductive (ovary cells) human tissues42. 213 
HMGCR transcription and degradation depends of a sterol/non-sterol feedback regulation but not 214 
directly controlled by cholesterol molecule. Under cholesterol depleted conditions, SREBP-SCAP 215 
complex is formed in ER membrane (without any INSIG interaction) then, it is transported to GB 216 
where SREBP is activated by proteolytic events facilitating its translocation into the nucleus to 217 
activate HMGCR transcription (Figure 3a). On the contrary, in cholesterol exceeding conditions, 218 
high amount of oxysterols are synthetized by the mitochondrial sterol 27-hydroxylase (CYP27A) 219 
and several mechanisms reducing HMGCR transcriptional rates are activated43. The HMGCR 220 
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regulatory mechanisms could be classified in INSIG-dependent (modulating at transcriptional and 221 
post-transcriptional levels), or INSIG-independent.   222 
     INSIG-dependent HMGCR regulation mechanisms (Figure 3b):  223 
- INSIG can disrupt SREBP activation by binding to SCAP when high sterol concentrations are 224 
noticed in the cytosol. Once INSIG-SCAP complex is formed, SCAP is structurally altered impairing 225 
the SREBP recognition and stopping the assembly of SREBP-SCAP complex for his further transport 226 
from ER (endoplasmic reticulum) to GB (Golgi body). In consequence, SREBP is not translocated to 227 
the nucleus and HMGCR transcription is inactivated17,44.  228 
- Under similar conditions, INSIG can also binds to the N-terminal region of HMGCR and conjugate 229 
it with ubiquitin. Ubiquitation is carried out by gp78 (membrane-bound ubiquitin E3 ligase) assisted 230 
by Ubc7 (an E2 ubiquitin conjugating enzyme) providing active ubiquitins and a few other enzymes. 231 
Then, ubiquitinated HMGCR is released into the cytosol and subsequently proteosome-degraded 232 
with the participation of p97/VCP (ATPase associate to membrane).      233 
However, the presence of high levels of sterols is not mandatory for the ubiquitination 234 
process but it stimulate HMGCR degradation by enhancing INSIG-HMCR bindings44.  235 
INSIG-independent HMGCR regulation mechanisms (figure 3b):  236 
- HMGCR activity could be also modulated in situations of cellular stress (low ATP levels) by 237 
AMPkinase (AMP-activated protein kinase). In this case, HMGCR is inactivated by a serine 238 
phosphorylation due to the AMPkinase activity. It is a reversible reaction and HMGCR can also be 239 
activated by the protein phosphatase 2A (PP2A)44,45.  240 
- Non-sterol isoprenoids might also modulate HMGCR translation by a mechanism still unclear 241 
according to Burg et al. (2011)44. 242 
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2.4. Molecular events occurring during cholesterol excretion 243 
For several decades, classical reverse cholesterol transport (RCT) was considered the main 244 
mechanism to eliminate cholesterol however, recent studies suggest another possible pathway 245 
called transintestinal cholesterol excretion (TICE)17.  246 
RCT is a derivative branch of the hepatobiliary pathway. Lipoproteins such as HDL or LDL 247 
make available cholesterol for hepatic absorption as esterified or non-esterified molecules. 248 
Esterified cholesterol is transformed by the hepatic cholesteryl ester hydrolase (NCEH1) into the 249 
non-esterified form after hydrolysis of the ester linkage. Thus, the generated forms are directly 250 
excreted through the ABCG8/5 heterodimer protein or transformed into bile salts46. CYP7A1 251 
(cholesterol 7alpha-monooxygenase) is the enzyme responsible for cholesterol transformation 252 
into primary bile salts (cholic and chenodeoxycholic acid) within the neutral bile acids pathway in 253 
liver. Synthesized bile salts are secreted to bile canaliculus by the bile salt export pump (BSEP) or 254 
the multidrug resistance-associated protein 2 (MRP2) and become part of bile fluids. Recent in vivo 255 
studies have suggested the involvement in RCT of other cholesterol transporters such as 256 
NPC1L120,47 although its role on biliary cholesterol excretion is not yet elucidated. But, it might 257 
involve adjustments in cholesterol balance to avoid excessive loss of the metabolite through the 258 
intestinal track.  259 
TICE have been suggested as an alternative cholesterol excretion mechanism where the 260 
sterol is directly eliminated from blood through the intestinal mucosa and excreted via feces17. The 261 
hypothesis was drawn after the unexpected results obtained by several authors that noticed an 262 
unwarranted balance between cholesterol inputs and outputs in mouse models. They showed a 263 
higher amount of fecal cholesterol than the sum of dietary intake and biliary secretion48 or an 264 
unaltered cholesterol excretion rate in knockout NPC1L1 mice with a decreasing of 90% biliary 265 
excretion49. 266 
These results questioned the complete RTC classical concept50 as well as the contribution 267 
of biliary or non-biliary cholesterol to its RCT excretion51. Although the involvement of several 268 
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membrane transports in TICE have been studied (i.e. SR-B152, NPC1L153, APOA154, LDLR or 269 
ABCG5/855), it is still unknown whether TICE is carried out through the basolateral or apical 270 
transporters or whether HDLs are involved56 therefore, the mechanism is not yet elucidated. There 271 
is also scientific controversy about the TICE importance, some authors suggest that it could be only 272 
a compensatory cholesterol excretion mechanism in case of biliary cholesterol depletion but, other 273 
authors pointed it as the main mechanism in cholesterol excretion. Van der Velde et al. (2007, 274 
2010) estimated TICE contribution as 70 and 30% of total cholesterol excretion respectively in mice 275 
and humans48,56.  276 
2.5. Molecular events occurring during cholesterol transport 277 
HDL, IDL (intermediate-density lipoprotein) , LDL and VLDL (very low-density lipoprotein) 278 
are the connecting structures responsible for transporting of cholesterol molecules through the 279 
blood stream from one tissue to another until they are detected by cellular membrane receptors 280 
such as SR-B1 for HDL or LDLR (LDL-receptor) for both structures.  281 
The non-esterified cholesterol eliminated by ABCA1 through the basolateral membrane of 282 
enterocytes is bound to APOA1 generating nascent-HDL and the esterified cholesterol is similarly 283 
assembled with APOB48 in ER synthetized pre-chylomicrons further transformed into 284 
chylomicrons in GA and excreted by exocytosis to intracellular space. Therefore, both structures 285 
become cholesterol transporters and they distribute it via the blood stream to the rest of the 286 
organism.  287 
Nascent HDL is transformed into mature HDL by accumulation of non-esterified cholesterol 288 
molecules secreted by hepatocyte and enterocyte ABCA1 protein. Once mature HDLs are formed, 289 
some cholesterol molecules are esterified by action of lecithin—cholesterol acyltransferase (LCAT) 290 
along it blood transport. Esterified and non-esterified cholesterol are detected by the SR-B1 291 
located in the basolateral membrane of cells from liver, small intestine or gland adrenals allowing 292 
the incorporation of esterified cholesterol inside the cell. Intracellular esterified cholesterol is 293 
transformed into non-esterified cholesterol (by SOAT action) and HDL is turned into LDL. The non-294 
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esterified cholesterol can be used for bile salts synthesis and their further intestinal secretion by 295 
BSEP or to be directly excreted via ABCA1 (basolateral membrane) and ABCG5/ABCG8 (apical 296 
membrane) activity. In turn, secreted non-esterified cholesterol again could be attached to nascent 297 
HDL to create mature HDL and continue with cholesterol transport. 298 
LDL molecules are recognized by liver, intestine and adrenal gland LDLRs as esterified 299 
cholesterol suppliers. LDL particles can be generated not only by VLDL transformation (by SR-B1 300 
activity) but also by addition of esterified cholesterol to APOB100 (apolipoprotein isoform 301 
characteristic of hepatocytes) leading to very low density lipoproteins (VLDL). These structures are 302 
secreted to blood stream by hepatocytes. VLDL lipids are used by the muscle and peripheral tissues 303 
as they pass through the blood stream generating IDL and LDL by lipoprotein lipases (LPL) activity. 304 
Moreover, esterified cholesterol of chylomicron structures is also recognized by LDLR providing to 305 
the hepatocyte those cholesterol molecules assembled in enterocytic ER after digestion process. 306 
The complex cholesterol biosynthesis and absorption enginery and the multifactorial 307 
regulation system make the control of cholesterol metabolism a difficult challenge for the scientific 308 
community. Particularly because some of the involved compounds are also intermediates of other 309 
metabolic pathways i.e LXR modulates ABCG5/8 activity but also DIO1, a selenoprotein involved in 310 
the thyroid hormone metabolism. However, these facts are also making it a flexible system that 311 
could be modulated from different critical points. 312 
3. Fungal molecules modulating cholesterol metabolism  313 
Many food compounds have been described as modulators of cholesterol homeostasis 314 
interacting with specific control points and inhibiting or altering cholesterol metabolism; even 315 
some in vivo studies suggest synergistic hypocholesterolaemic activities between several 316 
inhibitors57-59. Those compounds showed different targets depending if they modulate cholesterol 317 
absorption, synthesis, excretion or transport.  318 
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Intake of dietary fibers (DF) from cereals etc., increase cholesterol and bile acids excretion rates 319 
lowering their bioavailability because they might act as bile acid scavengers. This mechanism 320 
impair bile acids re-absorption stimulating the hepatic synthesis of new bile acids from cholesterol 321 
reducing its blood concentration10,60,61 although for particular β-glucans, modulation of 322 
cholesterol-related gene expresions have been also noticed62. 323 
Plant sterols (phytosterols and phytostanols) are considered direct cholesterol competitors 324 
for their incorporation into DMMs because of their structural similarity and due to the limited 325 
capacity of DMMs to solubilize lipophilic and water-insoluble molecules63-65. Some reports also 326 
suggested that phytosterols might modulate SOAT activities although it still remains partially 327 
unclear. Cholesterol enterocytic esterification by ACAT(AvS) was decreased by sterols competition 328 
although the enzyme showed lower esterification efficiency for plant sterol than cholesterol. Other 329 
authors suggested that plant sterols influenced MTTP and APOB48 lipoprotein in vitro models65.   330 
Compounds such as novel amino β-lactams derivates66 or curcuminoids polyphenols were 331 
described as potential NPC1L1 inhibitiors by showing high binding affinity or acting by indirect 332 
influence on SREBP137. ABCG5/8 postranscriptional regulations were also described for 333 
spironolactones or polyphenols from Aronia Melanocarpa67,68.  334 
Other compounds from natural sources have been reported as ACAT(AvS) inhibitors reducing 335 
cholesterol esterification rates such as alkamides from Piper nigrum69, shikonin derivatives from 336 
Lithospermum erythrorhizon70, an isoprenyl flavonoid identified as grabol from licorice roots71, 337 
ursolic acid (indirect inhibition via (PPAR)-α activation)72 or flucoxanthin from marine plants73.   338 
3.1.  Hypocholesterolemic compounds of edible mushrooms 339 
A few specific bioactive compounds are already pointed as responsible for the 340 
hypocholesterolaemic properties of mushrooms. The most extensively investigated are fungal 341 
sterols (ergosterol are its derivatives such as ergost-22-ene-1,3-diol, ergosta-5,7-dien-3b-ol, (22E)-342 
ergosta-1,4,6,22-tetraen-3-one, etc.) and β-glucans together with other dietary fibres. 343 
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Ergosterol (ergosta-5,7,22-trien-3β-ol) is considered the major fungal sterol (from 53% up to 344 
80% of the fungal sterols, w/w) followed by ergosterol derivatives such as ergosta-5,8,22-trien-3-345 
ol, ergosta-7,22-dien-3-ol, ergosta-5,7dien-3-ol and ergosta-7-en-3-ol (fungisterol)74.  However, 346 
their precise concentration in the different mushroom strains was dependent on environmental 347 
conditions (developmental stage, cultivation conditions etc.) or specie. For instance, Chantharellus 348 
cibarius and Craterellus cornucopioides showed almost exclusively ergosterol, while other species 349 
showed more ergosta-5,7-dienol than fungisterol (Lyophyllum shimeji or Pleurotus ostreatus). 350 
Flammulina velutipes contained high amounts of ergosta 5,8,22-trien3-ol10.  351 
Apparently, the hypocholesterolaemic activities of fungal sterols were mainly due to their 352 
structural similarity with cholesterol as noticed for plant sterols. Therefore, these compounds were 353 
able to hinder cholesterol incorporation into DMMs as phytosterols and phytostanols.          354 
Ergosterol-enriched fractions obtained using green technologies such as supercritical fluids 355 
extraction (SFE), were more effective than β-sitosterol in displacing cholesterol from DMMs during 356 
an in vitro digestion model59.  Moreover, fungal sterol-enriched extracts also showed HMGCR 357 
inhibitory activities in vitro75 and ergosterol was also considered as a competitive inhibitor of C24-358 
reductase due to its double bond at C-22 in the side chain of its structure (as also noticed for 359 
stigmasterol and brasicasterol). The C24-reductase is another enzyme involved in the cholesterol 360 
biosynthetic pathway down-stream from HMGCR76.  361 
Fungal β-glucans showed different molecular structures than cereal polysaccharides. Their 362 
branching profiles are (13) and (13)(16) conferring them many biological activities such as 363 
antitumoral, antioxidant, immunomodulatory etc. despite hypocholesterolaemic properties10,77,78. 364 
Some reports suggested that those bioactive properties are due to their different tridimensional 365 
configuration depending on their monomer composition, branching degree or conformation while 366 
other authors considered their water solubility (that is also partially dependent on their glycosidic 367 
linkages) a more relevant factor, considering those water-insoluble as the responsible for the 368 
cholesterol lowering activities by impairing cholesterol absorption.  Moreover, other publications 369 
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pointed β-glucans degradation products (generated i.e. after a digestion process) as 370 
hypocholesterolemic molecules more bioactive than their larger precursors10,79. However, until 371 
now the precise structural requirements for the observed hypocholesterolemic action of fungal β-372 
glucans remains unclear awaiting further studies.  373 
β-Glucans from a large number of mushroom species have been studied such as lentinan from 374 
shiitake mushrooms (Lentinula edodes), schizophyllan from Schizophyllum commune, grifolan from 375 
Grifola frondosa, and many others from Agaricus blazei, Ganoderma lucidum (a medicinal 376 
mushroom consumed as nutraceutical or dietary supplement), P. ostreatus as well as the (13) β-377 
glucans and glucuronoxylomannans from Auricularia polytricha and Tremella fuciformis80,81. They 378 
all showed different conformations, solubility and therefore biological properties.  379 
Chitin, a special type of water-insoluble β-(1→4)-glucan including N-acetylglucosamine 380 
monomers, is also considered an hypocholesterolaemic polysaccharide while its derivative, named 381 
chitosan, was more studied because of its antitumor and immunomodulation activities10,77. Several 382 
polysaccharide fractions (containing high percentages of fungal β-, α-glucans and 383 
chitooligosacharides among others) from L. edodes, P. ostreatus and A. bisporus extracted by using 384 
pressurized technologies (PSE) showed bile acid binding capacities in vitro similar to those shown 385 
by cereals fibers82 indicating that might impair cholesterol absorption as previously suggested for 386 
plant β-glucans. 387 
According to Gunde-Cimerman et al. (1993, 1995) suggestions, lovastatin an inhibitor of 388 
HMGCR (3-hydroxy-3methylglutaryl-Coenzime A reductase), was naturally present in some 389 
Pleurotus spp. fruiting bodies such as P. ostreatus or P. eryngii83,84 and in other species such as A. 390 
bisporus or B. edulis. However, recent studies did not detect any statin in mushroom species 391 
showing interesting HMGCR inhibitory activity pointing to some water soluble polysaccharides and 392 
proteoglucans as the responsible for the noticed in vitro inhibition10,75. 393 
HMGCR inhibition was also mediated by an AMP kinase via phosphorylation and green and 394 
black tea polyphenols induced a direct increase of HMGCR phosphorylation possibly via AMP 395 
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kinases phosphorylation. Their precise mechanism of action is still unclear but, it seems to involve 396 
activation of regulatory factors such as PPAR85,86. 397 
Only a few compounds are still nowadays pointed as potential inhibitors of the SQS such 398 
as resveratrol from wine87as well as zaragozic acids isolated from the liquid broth of certain 399 
ascomicetes100.   400 
24(S), 25-epoxycholesterol was also pointed as inhibitor of the DHCR24 activity. This 401 
enzyme catalyze the transformation of desmosterol into cholesterol. The inhibitor did not modify 402 
DHCR24 protein levels, but increased desmosterol accumulation decreasing cholesterol levels in 403 
in vitro studies due to its structural similarity with desmosterol88.  404 
3.2 Molecular events modulated by mushroom extracts 405 
The presence of certain natural molecules in mushrooms do not only modify cholesterol 406 
absorption or metabolic pathway of consumers but can also modulate the expression of some 407 
genes related to cholesterol homeostasis. Recent studies carried out on particular edible 408 
mushrooms studied their influence as attempt to further identify the most interesting fungal 409 
compounds to treat moderate hypercholesterolemia. 410 
Mushrooms such as Pleurotus ostreatus, Grifola frondosa and Hypsizigus marmoreus were 411 
able of differently modulating the gene expression patterns of mice livers fed with each 412 
mushroom (10-14%) for 4 weeks. Triglyceride levels in liver and plasma decreased in the mice fed 413 
with P. ostreatus compared with those in the control group. Moreover, liver cholesterol decreased 414 
while plasma total cholesterol increased probably due to HDL values that were also increased. 415 
Cholesterol in the liver was lower in the group fed with G. grondosa than in the control group but 416 
no changes were found in the H. Marmoreus-fed group. DNA microarrays analysis of the livers 417 
revealed that CTP1A and FABP families were upregulated in the P. ostreatus-fed group, which 418 
were considered to promote lipid transport and β-oxidation. In the G. frondosa-fed group, not 419 
only the gene involved in signal transduction of innate immunity via TLR3 and interferon but also 420 
virus resistance genes (such as MX1, RSAD2 and OAS1) were upregulated89.  421 
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Administration of Agaricus brasiliensis (also known as Agaricus blazei) to 422 
hypercholesterolemic albino Fischer rats during 6 weeks lowered cholesterol levels in serum and 423 
induced significant changes in the expression of cholesterol-related genes. HMGCR mRNA 424 
expression was not influenced but LDLR upregulation was noticed together with upregulation of 425 
CYP7A1, the rate-limiting enzyme for bile acid synthesis, and mRNA levels of the ABCG5/8 carriers. 426 
These increases were accompanied by a significant increase in the content of cholesterol excreted 427 
in the faces and by a concomitant increase in NR1H3 (LXR) mRNA levels. However, in this case 428 
PPAR-α was not significantly upregulated compared with levels noticed in the 429 
hypercholesterolemic control group90.  430 
In a few reports specific extracts and not the whole fruiting body were studied. For instance, 431 
ethanol (95%) extracts obtained from P. ostreatus were administrated to hypercholesterolemic 432 
Male Wistar rats during 14 days and a reduction of triglycerides and HDL cholesterol was noticed 433 
in plasma. Moreover, the extract was able of up regulate the genes that were downregulated after 434 
hypercholesterolemia induction such as those related to fatty acids oxidation such as acyl CoA 435 
oxidase (ACO) and synthetase (ACS) together with carnityl palmityl transferase-1 (CPT-1) and 436 
PPAR-α. They also downregulated genes related to the fatty acids biosynthesis and cholesterol 437 
metabolism (FAS fatty acid synthase, SREBF1, APOC3) to similar expression than during 438 
normocholesterolemia91. 439 
 Hericium erinaceus hot water and ethanol extracts were administrated together with a high-440 
fat diet to C57BL76J mice for 4 weeks. Incorporation of the extracts in the diet resulted in a 441 
significant decrease in body weight, fat and serum and hepatic triglicerides levels compared to 442 
control. The ethanol extract was acting as an agonist of PPAR-α since it was able of up-regulating 443 
mRNAs usually modulated by PPAR-α (ACAT, ApoA1, LPL or SREBP1) in spite of the fact that the 444 
PPAR-α expression itself did not change92.  445 
An extract obtained from cauliflower mushroom (Sparassis crispa) significantly enhanced 446 
hepatic cholesterol catabolism when administrated to Male Sprague-Dawley rats fed 447 
19 
 
a cholesterol-rich diet for 4 weeks because they were able of up-regulating CYP7A1 mRNA 448 
expression concomitant with HMGCR downregulation after. Additionally, the extract 449 
supplementation resulted in cholesterol and bile acid fecal excretion93.  450 
3.3 Molecular events modulated by fungal sterols 451 
Since plant and fungal sterols share structural similarities, similar modulation of cholesterol 452 
related genes might also be expected. However, in the few studies carried out using fungal sterols 453 
different effects were noticed.  454 
Ergosterol was able of regulating sterol regulatory element binding protein (SREBP) 455 
cleavage in yeast as response to cellular oxygen levels94 suggesting that it might also modulate 456 
these elements in mammalians. Studies carried out using cell cultures revealed that DMMs isolated 457 
from in vitro digestion of ergosterol and extracts containing ergosterol mixed with cholesterol were 458 
not influencing transcriptional levels of SREBF1 differently than when only cholesterol was 459 
administrated. Moreover, only a slight inhibition was noticed for SREBF2 mRNA of Caco2 cells when 460 
treated with an ergosterol-containing extract but not with ergosterol itself. However, other 461 
cholesterol related genes were also overexpressed such as the LDLR (when an ergosterol-enriched 462 
extract from Agaricus bisporus was applied)15. When the lower compartment of the Caco2 cells 463 
supplemented with the sterol-containing digested extracts were added to HepG2 cells, higher 464 
modulation of genes related to the lipid metabolism was noticed than those more directly related 465 
to the cholesterol homeostasis such as DGAT2 upregulation.  466 
When similar extracts were given for 4 weeks to C57BL/6JRj mice previously fed for 4 467 
weeks with hypercholesterolemic diets, inhibition of SREBF2 and NR1H4 (gene enconding FXR) 468 
were noticed in jejunum up to similar levels than hypocholesterolemic drugs such as ezetimibe and 469 
simvastatin15. This downregulation was due to their ergosterol content because supplementation 470 
with purified ergosterol induced similar modulation. FXR is the farnesoid X receptor, a nuclear 471 
receptor also involved in the regulation of cholesterol homeostasis95. FXR is involved in the 472 
activation or inhibition of bile acids synthesis and transport acting as a sensor of their 473 
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concentration96. The extract induced downregulation of DGAT2 in liver as observed in cell cultures 474 
but upregulation of FDFT1, might be to compensate for the reduction on the ratio TC/HDL 475 
recorded. Reduction on the triglycerides levels were also noticed in liver, perhaps because of the 476 
observed modulation on DGAT2 gene transcription. Moreover, this extract induced overexpression 477 
of DIO1 mRNA in jejunum, the tissue where cholesterol absorption is higher97. Type I iodothyronine 478 
deiodinase is a selenoprotein encoded by DIO1 gene and play a major role in normal thyroid 479 
function, but it is also indirectly influencing cholesterol homeostasis by regulating the LDLR gene 480 
expression. Increased DIO1 activity in liver correlated with up-regulation of the LDLR mRNA and 481 
lowering of TC, TG and LDL levels in serum15. However, no significant effect was noticed by Gil-482 
Ramirez et al., 201597 on the latter gene, perhaps the supplemented concentration was sufficient 483 
to stimulate DIO1 but it did not revert on LDLR readjustments. On the contrary, ergosterol 484 
administrated as single compound induced downregulation of DIO1 mRNA therefore the effect of 485 
the ergosterol enriched extract could be due to some other sterol or compound present in the 486 
extract97. 487 
However, when the ergosterol containing extracts were incorporated into lard and the 488 
mixture supplemented together with the diet to induce hypercholesterolemia, insignificant effects 489 
were noticed on any SREBP, other cholesterol regulatory nuclear receptor or genes involved in the 490 
cholesterol metabolism except for ABCG5 and 8 mRNAs expression in cecum that were up-491 
regulated. Perhaps the addition of the extract as ingredient inside a lipid matrix prevented their 492 
proper bioavailability (because it was also unable of lowering cholesterol levels in serum, HDLc or 493 
LDLc) or perhaps the beneficial properties of ergosterol were not sufficient to overcome the 494 
detrimental effect of lard and the hypercholesterolemic diet when administrated simultaneously98. 495 
Transcription of some ABC transporters (ABCG5/8 etc.) was induced by LXR factor in 496 
enterocytes (but not in hepatocytes)65 although, there is a controversy about its influence on other 497 
transporters (ABCA1). Oxysterols such as 22(R)-hydroxycholesterol, 24(S),25-epoxycholesterol or  498 
27-hydroxycholesterol etc., are considered as endogenous natural LXR agonist however, plant 499 
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sterols derivatives showed higher LXR agonist activity. Brasicasterols from unicellular algae and 500 
Brassiceas sp (i.e. rapeseed) induced large variations in the gene expression of ABC transporters 501 
due to their ability to act as the LXR factor in mice. Moreover, sitostanol (in mice), sitosterol (in 502 
Caco2 cells) and a few 4-desmethylsterol derivatives were also able of inducing ABCA1 up-503 
regulation using their LXR agonist activity5,11,13,65. However, no direct effects of phytosterols or 504 
fungal sterols were noticed on the transcriptional levels of the transporters because on the one 505 
hand, in ABCA1 and ABCG5/8-deficient mice decreasing of cholesterol intestinal absorption was 506 
also noticed after phytosterol administration indicating that ABC transporters were not their direct 507 
targets. On the other hand, no significant overexpression or repression was neither noticed in 508 
hypercholesterolemic C57BL/6JRj mice treated with ergosterol-containing extracts15. 509 
Other reports indicated that phytosterol/stanols modulated HMGCR expression via 510 
ACAT(AvS)  inhibition. Apparently, lower ACAT(AvS)  activity led to higher free cholesterol amounts, 511 
inhibiting the cholesterol biosynthetic pathway and HMGCR expression beside others. It also 512 
reduced chylomicron assembling, and promoted the back efflux of non-esterified sterols to the 513 
lumen11,65,99. However, their influence on SOAT seemed to be by chemical inhibition more than by 514 
molecular modulation. Direct down-regulation of HMGCR mRNA (together with inhibition of the 515 
enzyme) was only noticed in organic extracts obtained from the Reishi mushroom (Ganoderma 516 
lucidum) containing oxygenated lanosterol derivatives. They also inhibited cholesterol synthesis in 517 
T9A4 hepatocytes and reduced total cholesterol in hamsters100. 518 
Several in vitro studies pointed out that SREBP2, NPC1L1 and SR-B1 gene expression was 519 
modulated by plant sterols such as stigmasterol and β-sitosterol toward the reduction of 520 
cholesterol absorption. Surprisingly, HepG2 cells treated with these sterols showed simultaneous 521 
down-regulation of NPC1L1 and SR-B1 when an opposite effect on these two molecules could be 522 
expected. This modulation was not noticed when fungal sterols were applied to the hepatic cells 523 
15 neither when administrated to mice together with a hypercholesterolemic diet98. Studies using 524 
homozygous and heterozygous knockout mice (NPC1L1-/- and NPC1L1+/-) showed a lower 525 
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cholesterol absorption in homozygous animals however, heterozygous mice showed higher 526 
HMGCR mRNA levels in gut and liver tissues than wild-type animals without changes in ABC 527 
transporters expression rates. Authors explained their results by compensatory effects: difficulties 528 
for cholesterol absorption were compensated by a stimulation of endogenous cholesterol 529 
synthesis to maintain physiological plasma levels101,102. Moreover, when the knockout mice were 530 
treated with plant sterols or ezetimibe, the wild-type and heterozygous animals showed a 531 
reduction in cholesterol and TG levels. Absorption of campesterol and β-sitosterol was reduced in 532 
NPC1L1+/- and almost absent in NPC1L1-/- mice indicating that certain modulation of NPC1L1 took 533 
place101,102. However, no modulation of NPC1L1 expresion was noticed in C57BL/6 mice fed a fungal 534 
sterol extract together with a hypercholesterolemic diet98. 535 
Moreover, β-Sitosterol addition to Caco2 cultures induced down-regulation of HMGCR 536 
expression although this effect was not noticed in mice. Only sitosterolemic individuals showed 537 
reduction in HMGCR activity in ileum so apparently only large amounts of plan sterols or  long-538 
term 2% (w/w) plant sterol administration can induce such effect11,103.  539 
Other reports indicated that phytosterols might modulate the expression of other closely 540 
related genes such as those encoding the hepatic cholesterelogenic farnesyl phosphate synthase 541 
(FFPS), liver CYP7A1 (cytochrome P450 family 7 subfamily A polypeptide 1) or  anexin 2-Caveolin 542 
1 (ANXA2-CAV1) protein complex11. Therefore, fungal sterols might be involved in the modulation 543 
of CYP7A1 noticed during the administration of the complete mushroom fruiting bodies to 544 
hypercholesterolemic mice90.  545 
3.4 Molecular events modulated by fungal polysaccharides 546 
At the present, not many studies have been carried out concerning the molecular effect of 547 
dietary fibers independly of their plant or fungal origen. However, already in 1996, Cheung reports 548 
suggested that fungal polysaccharides extracts could modulate cholesterol related enzymes 549 
activity (HMGCR) by several mechanisms and not only via direct inhibition. Later on, several 550 
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studies were carried out to investigate the molecular role of fungal polysaccharides on cholesterol 551 
metabolism78.  552 
Fukushima et al. (2000)104 examined the effects of a fiber extract obtained from Agaricus 553 
bisporus on the LDLR mRNA expression after feeding rats with cholesterol-free diets during 4 554 
weeks. Despite a higher relative liver weight in control group (cellulose supplementation) 555 
comparing with those animals fed with the mushroom fiber extract as supplement, serum total 556 
cholesterol, VLDL and LDL concentrations in the control group were significantly greater than 557 
animals fed the A. bisporus fiber. Added to this, once LDLR mRNA hepatic levels were analyzed, 558 
results showed that mushroom LDLR up-regulation was significantly higher than that induced by 559 
cellulose fiber supplement104. One year later, the same group reported that maitake (Grifola 560 
frondosa) and enokitake (Flammulina velutipes) fiber extracts lowered total serum cholesterol 561 
levels by two mechanisms, by scavenging cholesterol molecules inducing their fecal excretion and 562 
by enhancement of LDLR mRNA expression in rat liver105. However, no up-regulation was 563 
significantly noticed when rats were fed shiitake (Lentinula edodes) fiber extracts.   564 
Dietary fibres fractions from P. ostreatus, L. edodes and A. bisporus fruiting bodies obtained 565 
as described by Jeurink et al. (2008)106 including a low α-glucans amount and high concentrations 566 
of chitin derivatives and other β-glucans82 were also added to Caco2 cells to study their effect on 567 
the most interesting cholesterol-related genes. The transcriptomic profile was studied after 1 and 568 
24h application and results indicated that the fiber extracts obtained from P. ostreatus were able 569 
of modulating transcription of more genes related to the cholesterol metabolism than the other 570 
two mushroom studied at longer incubation times. Up-regulation of FDFT1 and NPC1L1 was 571 
noticed together with slight modulation of a few others mRNAs therefore, in vivo experiments 572 
were carried out using P. ostreatus fiber extract using two different experimental settings. In the 573 
first one, C57BL/6J mice were firstly administrated hypercholesterolemic diets and then, 574 
supplemented with the fiber extract (as palliative treatment) and in the second experiment, mice 575 
were simultaneously fed with hypercholesterolemic diet plus fiber extract (preventive treatment). 576 
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Results indicated that their molecular responses were completely dependent on the 577 
supplementation setting. In the palliative setting, administration of the fiber extract reduced 578 
hepatic triglyceride levels and it might be because of the DGAT1 downregulation also recorded. In 579 
the preventive setting, the fiber extract modulated cholesterol-related genes expression similarly 580 
to simvastatin and ezetimibe in liver (i.e. by inhibiting FDFT1, NR1H3 (LXR) and NR1H4 (FXR) mRNA 581 
expression) although no changes in plasma and liver biochemical data was recorded107. Later on, 582 
when similar extract was applied in a higher concentration and mixed with lard, the 583 
hypocholesterolemic effect was noticed (as reduction of TC and LDLc levels) but no relevant 584 
modulation of cholesterol-related gene transcription was noticed despite overexpression of 585 
NPC1L1 in mice liver and jejunum98. 586 
The molecular modulations noticed for fungal β-glucans seemed to be different than other 587 
dietary fibers obtained from plants i.e. high viscosity oat or barley β-glucan extracts demonstrated 588 
their ability to down-regulate SREBF2 gene expression in intestinal cells (NCl-H716) 62 but no with 589 
in vivo testing. However, according to Hu, Wang & Xu (2008) corn bran dietary fiber up-regulated 590 
the expression of other genes such as FXR in ileal cells or PPAR in liver108. 591 
Hepatic HMGCR up-regulation was observed after administration of hydroxylpropylmethycellulose 592 
or inulin-oligofructose (1:1) to animal models109,110 however, barley β-glucans administration 593 
induced no changes on HMGCR expression111. Jones (2008)111 noticed hepatic SREBF2 up-594 
regulation when soluble dietary fiber (guar gum, a galactomannan) was administrated to pigs. In 595 
consequence, LDLR expression was enhanced and reduced the LDLs from the blood stream. Fungal 596 
fibers instead seemed to modulate directly LDLR mRNA expression104,105. Hepatic ABCG5/8 gene 597 
expression was also enhanced by guar gum consumption leading a higher cholesterol efflux from 598 
the liver to intestinal lumen111. A similar enhancement together with ABCA1 mRNA was noticed in 599 
jejunum from mice administrated P. ostreatus fibers (palliative treatment) but without significant 600 
cholesterol reduction107.  601 
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Other studies indicated that the scavenging of bile acids by plant fiber (β-glucans) activated 602 
CYP7A1 to convert cholesterol into new bile acids108,112 provoking an hepatic cholesterol decrease 603 
that up-regulated LDLR expression and reduced cholesterol blood levels. Due to these changes, the 604 
biosynthetic pathway was also activated via HMGCR up-regulation to compensate the lack of 605 
hepatic cholesterol112,113. However, the effect of fungal fibers on CYP7A1 is still at the present 606 
unknown.  607 
Other studies were carried out using extracts containing the water soluble 608 
polysaccharides from L. edodes. This fraction contained α- and β-glucans and fucomannogalactans 609 
that when digested (in vitro) were applied to Caco2 cell cultures and no significant effect was 610 
noticed on the modulation of cholesterol-related gene expression. But, when the lower 611 
compartment of the cell monolayer was applied to HepG2 modulation of some mRNAs were 612 
noticed after 24h incubation. However, the modulatory pattern fitted more with a low cholesterol 613 
level response since enzymes such as HMGCR, FDFT1 and ACAT1 were overexpressed, perhaps 614 
the HMGCR inhibitory activity showed by this extract was inducing a posttranscriptional 615 
cholesterol reduction that activated the biosynthetic pathway after 24h114. Later on, when this 616 
extract was administrated to normocholesterolemic mice for 4 weeks similar overexpression of 617 
HMGCR (in liver) and FDFT1 (in jejunum) were noticed. However, when the extract was 618 
administrated to hypercholesterolemic mice the modulation profile showed similarities with 619 
those generated after administration of ezetimibe, simvastatin or both such as for instance down-620 
regulation of FDFT1 (in ileum), SREBF2 or NR1H4 (in jejunum) or up-regulation of ABCG8 or ACAT1 621 
in jejunum. 622 
Other polysaccharides extracted from 3 different strains of Pleurotus tuber-regium, when 623 
administrated to obese-diabetic rats for 8 weeks, also showed and hypolipidemic effect that was 624 
associated with up-regulated liver PPAR-alpha mRNA expression and protein levels. Moreover, 625 
hyperglycemia was aslo attenuated by the polysaccharides, the elevated serum total cholesterol, 626 
triglycerides and low-density lipoprotein (LDL) concentrations were controlled, and parallel 627 
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restoration of decreased high-density lipoprotein (HDL) levels were noticed after their 628 
supplementation115. 629 
3.5 Molecular events modulated by other fungal compounds 630 
An adenosine analogue alkaloid (eritadenine) is another compound from L. edodes able of 631 
inhibiting the S-adenosylhomocysteine hydrolase, a key enzyme for the hepatic phospholipid 632 
metabolism. This inhibition could be related to the lowering of cholesterol levels in serum noticed 633 
in animal studies116,117. Eritadenine increases the hepatic microsomal phosphatidylethanolamine 634 
(PE) concentration and decreases the liver microsomal ∆6-desaturase activity, altering the fatty 635 
acid and molecular species profile in liver and plasma. When it was administrated to rats, 636 
suppression of 6-desaturase activity was accompanied by a significant reduction in the 637 
abundance of mRNA for the enzyme suggesting that dietary eritadenine might suppress the activity 638 
of liver microsomal 6-desaturase by altering the microsomal phospholipid profile and this effect 639 
was mediated by the regulation of the enzyme transcription118. Eritadenine was also involved in 640 
the up-regulation of the CYP7A1 expression noticed in liver of hypercholesterolemic mice fed the 641 
standard compound or 5, 10 or 20 % L. edodes119. 642 
Water extracts obtained by PWE (pressurized water extractions) from normal and selenium-643 
enriched A. bisporus were tested in vitro as HMGCR inhibitors. Selenium supplementation 644 
enhanced the inhibitory activity of statins and therefore, the latter extracts might improve their 645 
HMGCR inhibitory capacity. However, no significant differences were found, they both similarly 646 
inhibited the enzyme only if the extracts were not thermally treated.  When the extracts were 647 
applied to HepG2 cells to study their effect at the molecular level they also induced similar 648 
responses in most of the cholesterol-related genes. However, after 1h application overexpression 649 
of LDLR mRNA was noticed in non Se-fortified extracts. After 24h the LDLR mRNA was 650 
downregulated together with the FDFT1. Similar downregulation of the SQS mRNA was also 651 
noticed in Se-fortified extracts indicating that non-thermal water extracts from A. bisporus could 652 
inhibit transcription of this enzyme that is also a key enzyme downstream the cholesterol 653 
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metabolic pathway120. Reduced expression of GPX3 (glutathione peroxidase, a selenoprotein 654 
largely influenced by the presence of selenium in the media) was shown to increase cell-mediated 655 
oxidation of LDL and selenium supplementation (1 ppm) also induced downregulation of APOB and 656 
HMGCR expression during hypercholesterolemia in rat models. However, no significant 657 
modulation of the GPX397 and APOB120 expression was noticed neither in non- or Se-fortified 658 
extracts only a slight up-regulation of HMGCR after 1h for non-fortified extracts and after 24h for 659 
Se-fortified ones perhaps to compensate the inhibition of the FDFT1 transcription noticed120. 660 
4 Conclusion 661 
Consumption of edible mushrooms or functional foods containing specific fungal extracts 662 
should be encouraged within people with low to moderate hypercholesterolemia (before the use 663 
of pharmaceutical drugs) to lower their cholesterol levels in serum. As noticed for plants, cereals 664 
and other food derivatives, they contain specific compounds that can modulate cholesterol 665 
homeostasis via different transcriptional and post-traslational mechanisms that are nowadays, not 666 
completely understood but that they could be different than those described for plants. Thus, 667 
more studies are necessary to broad the knowledge toward the molecular effect of fungal 668 
compounds on human health since the results obtained up to now are promising, suggesting that 669 
their use as hypocholesterolemic foods might be more effective than those products actually 670 
offered in the markets. 671 
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Figure 1: Cholesterol and fat digestion and absorption pathway. PL: phospholipids, FA: fatty acids, 
BA: bile acids, TAG: triacylglycerols, CL: cholesterol, LPA: lysophosphatidic acid, MAG: 
monoacylglycerols, LPA: lysophosphatidic acid, CE: cholesterol esters, ABCG5: ATP-binding 
cassette subfamily G member 5, ABCG8: ATP-binding cassette subfamily G member 8, ABCA1: ATP-
binding cassette subfamily A member 1, ACAT2: Acetyl-CoA Acetyltransferase 2, FABPpm: Plasma 
membrane fatty acid-binding protein, NPC1L1: Niemann-Pick C1-like protein, SRB1: Scavenger 
receptor class B member 1, AGPAT: 1-acylglycerol-3-phosphate O-acyltransferase, LPAT: 
lysophosphatidate acyltransferase , MGAT2: monoacylglycerol acyltransferase-2, DGAT1: 
diacylglycerol O-acyltransferase 1, MTTP: microsomal triglyceride transfer protein large subunit, 
APOB48: apolipoprotein B-48, APOA1: apolipoprotein A-1, ER: endoplasmatic reticle, GB: Golgi 
body, PCM: pre-chylomicron; CM: chylomicron. 
 
Figure 2: Cholesterol biosynthetic pathway from glycolysis product, Acetyl coenzyme A and 
Acetoacetyl coenzyme A. Ac-CoA: Acetyl coenzyme A; AcAc-CoA: Acetoacetyl coenzyme A; CoA: 
coenzyme A; HMG-CoA: 3-Hydroxy-3-methylglutaryl-CoA; A: Cholesta-7,24-dien-3β-ol; B: 
Cholesta-8-en-3β-ol; C: 7-Dehydro-desmosterol; D: Lathosterol; E: Desmosterol; F: 7-
Dehydrocholesterol; ACAT2: acetyl-CoA acetyltransferase 2; HMGCS: hydroxymethylglutaryl-CoA 
synthase; HMGCR: 3-hydroxy-3-methylglutaryl coenzyme A reductase; SQS: farnesyl-diphosphate 
farnesyltransferase or squalene synthetase; SQLE: squalene monooxygenase; DHCR24: delta24-
sterol reductase; DHCR7: 7-dehydrocholesterol reductase; SOAT: Sterol O-acyltransferase. 
 
Figure 3: Molecular regulation pathway of HMGCR transcription under low (a) and high (b) 
intracellular cholesterol levels. INSIG: Insulin induced gene 1 protein; SREBP: Sterol regulatory 
element-binding protein; SCAP: SREBP cleavage-activating protein; COP-II: Coat complex protein 
II; SPH2: Sphingosine kinase II; TMUB1: Transmembrane and ubiquitin like domain containing 1; 
gp78: Membrane-bound ubiquitin E3 ligase; Ubc2: Ubiquitin-conjugating enzyme E2 2; HMGCR: 3-
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Hydroxy-3-methylglutaryl-CoA reductase; SRE:Sterol regulatory element; RXR: retinoic X receptor; 
LXR: liver X receptor; ABCA1: ATP-binding cassette subfamily A member 1; ABCG5/8: ATP-binding 
cassette subfamily G member 5/8; SOAT: Sterol O-acyltransferase; UBQ: Ubiquitin; AMPK: AMP-
activated protein kinase; PP2A: Phosphatase 2A. 
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Figure 3b 
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Table 1: Chemical reaction, location within the metabolic pathway and within the cell of ACAT and SOAT, enzymes involved in cholesterol metabolism. M: 
mitochondrion; ER: endoplasmic reticle; Cy: cytoplasm; PM: plasmatic membrane; ExC: extracellular compartment. +: relative genes abundance  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACAT/SOAT are involved in  
mRNA subcellular location 
 
 
 Cholesterol 
synthesis  
Cholesterol 
absorption 
 Reaction 
Pre-
HMGCR 
Post-
HMGCR 
Small intestine 
(ER membrane) 
M ER Cy PM ExC 
ACAT 
[EC 2.3.1.9]      
yes no no +++ + ++ ND ND 
SOAT 
[EC 2.3.1.26] 
 
no yes yes ND +++ ND ++ + 
